Slide 1: Cover letter to stock exchanges
Biocon Limited 20th KM, Hosur Road Electronic City Bangalore 560 100, India T 91 80 2808 2808 F 91 80 2852 3423 CIN : L24234KA1978PLC003417 www.biocon.com May 19, 2021 To To The Secretary The Secretary BSE Limited National Stock Exchange of India Limited Department of Corporate Services Corporate Co
Slide 2: Investor Presentation Q4FY21 | May 2021
INVESTOR PRESENTATION Q4FY21 | May 2021
Slide 3: Safe Harbor Statement
Safe Harbor Statement Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking s
Slide 4: Biocon is a global biopharmaceutical company
Biocon is a global biopharmaceutical company that is leveraging its affordable innovation model to reduce disparities in access to safe, high- quality medicines, as well as, address the gaps in scientific research to find innovative solutions to impact a billion lives. 3
Slide 5: The Biocon Manifesto
The Biocon Manifesto accessibility affordability • Use our science, scale and • Focus on the kind of expertise to enhance access innovation that adds the to essential drugs for condition of affordability to As a committed patients on the lowest rung accessibility stakeholder of the of the economic l
Slide 6: The Biocon Journey: A Continuous Evolution
The Biocon Journey: A Continuous Evolution 1978- 2000- 2005- 2010- 2016- 2019 & 1999 2004 2009 2015 2018 Beyond An Transforming Building the Base Strategic Global Commercialized Poised for Enzymes into a Business and Alliance with Biosimilars for Global Impact Company Biopharma Expertise in Mylan fo
Slide 7: Biocon Today: Strategically poised for a strong global play
Biocon Today: Strategically poised for a strong global play Rs 7,360 Cr 12,000+ Revenue* Total Employees* 1,200+ 25+ Patents cGMP approvals from International regulatory agencies 120+ Ranked 5 Countries where our Among Top 10 Global products are available Biotech Employers by Science magazine *Fisca
Slide 8: Business Segments
Business Segments A
Slide 9: Growth Verticals: Aligned With Shifting Paradigms
Growth Verticals: Aligned With Shifting Paradigms From pipeline to production, from drug discovery to drug delivery, we bring differentiated, high-quality and affordable healthcare products & services globally. Ensuring Expanding Partnering to Pushing access access through deliver scientific through
Slide 10: Generics Business- Investing into capacities and capabilities for future growth
Generics Business- Investing into capacities and capabilities for the future growth Differentiated API business Growing Formulations Footprint Investments for future growth • 5 state-of-the-art facilities across • Solid oral & parenteral products in both • Expanding our R&D capabilities for newer Ba
Slide 11: Biocon Biologics: Developing biosimilars for global markets at all scale
Biocon Biologics: Developing biosimilars for global markets at all scale Biosimilars are an attractive opportunity Robust portfolio of biosimilars Fully integrated – lab to market Global Footprint (120+ countries) Strong partners e.g., Viatris and Sandoz Branded Formulations India (BFI) forms a robu
Slide 12: Novel Molecules: Pushing scientific boundaries to deliver impactful innovations
Novel Molecules: Pushing scientific boundaries to deliver impactful innovations Disease Area Asset Current Progress • Phase I multiple ascending dose studies in Type 1 DM patients making good Insulin Tregopil- a first-in-class oral, prandial progress in Germany. This trial is in partnership with the
Slide 13: Research Services (Syngene): A global CRO delivering innovative solutions
Research Services (Syngene): A global CRO delivering innovative solutions Offering integrated research, development and manufacturing services for both small and large molecules, antibody-drug conjugates and oligonucleotides backed by best-in-class bioinformatic services Combining world class resear
Slide 14: Financial Highlights
Financial Highlights A
Slide 15: Q4FY21 and FY21 Financial Highlights
Q4FY21 and FY21 Financial Highlights Particulars1 Q4FY21 Q4FY20 Change FY21 FY20 Change Total Revenue 2,044 1,621 26% 7,360 6,462 14% EBITDA 641 382 68% 1,907 1,765 8% PBT Before Exceptional Items 354 213 66% 1,065 1,147 (7%) PBT from Continuing Operations 366 213 72% 1,077 1,215 (11%) Net Profit fr
Slide 16: Revenue by Segments
Revenue by Segments Particulars1 Q4FY21 Q4FY20 Change FY21 FY20 Change Generics 578 562 3% 2,336 2,207 6% Biosimilars 664 433 53% 2,800 2,315 21% Novel Biologics - - - - - - Research services 659 607 8% 2,184 2,012 9% Inter-segment (61) (45) 35% (215) (234) (8%) Revenue from operations 1,839 1,558 1
Slide 17: Key Segment wise highlights
Key Segment wise highlights Particulars1 Q4FY21 Q3FY21 Q4FY20 FY21 FY20 Segment revenue Generics 578 561 562 2,336 2,207 Biosimilars 664 769 433 2,800 2,315 Novel Biologics2 - - - - - Research services 659 585 607 2,184 2,012 Total 1,900 1,914 1,603 7,320 6,534 Less: Inter-segment revenue (61) (63)
Slide 18: Thank You
Thank You INVESTOR RELATIONS CONTACT: Ankit Gupta, Biocon Limited Tel : +91 813 092 3253 Email: ankit.gupta@biocon.com Nikunj Mall, Biocon Biologics Limited Tel : +91 998 777 4078 Email: Nikunj.mall@biocon.com www.biocon.com 17